tiprankstipranks
Advertisement
Advertisement

ALLO Stock Latest News

Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks
Company AnnouncementsAllogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks
14d ago
ALLO
Allogene Therapeutics Banks on 2026 Trial Catalysts
PremiumCompany Announcements
Allogene Therapeutics Banks on 2026 Trial Catalysts
14d ago
ALLO
Allogene Therapeutics price target raised to $8 from $7 at Piper Sandler
PremiumThe Fly
Allogene Therapeutics price target raised to $8 from $7 at Piper Sandler
15d ago
ALLO
Allogene Therapeutics reports Q4 EPS (17c), consensus (22c)
PremiumThe Fly
Allogene Therapeutics reports Q4 EPS (17c), consensus (22c)
16d ago
ALLO
ALLO Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ALLO Earnings this Week: How Will it Perform?
26d ago
ALLO
3 ‘Strong Buy’ Small Cap Stocks to Buy for 2026, According to Analysts
PremiumMarket News3 ‘Strong Buy’ Small Cap Stocks to Buy for 2026, According to Analysts
2M ago
ALLO
BTBT
Midday Fly By: Job growth comes in below forecasts in December
Premium
The Fly
Midday Fly By: Job growth comes in below forecasts in December
3M ago
C
Z
Allogene Therapeutics upgraded to Outperform from Market Perform at Citizens
Premium
The Fly
Allogene Therapeutics upgraded to Outperform from Market Perform at Citizens
3M ago
ALLO
Allogene outlines 2026 as program-defining year for allogeneic CAR T
PremiumThe Fly
Allogene outlines 2026 as program-defining year for allogeneic CAR T
3M ago
ALLO
Allogene Therapeutics initiated with a Buy at UBS
PremiumThe Fly
Allogene Therapeutics initiated with a Buy at UBS
3M ago
ALLO
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
PremiumThe Fly
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
3M ago
ALLO
CLLS
Allogene Therapeutics’ ALPHA Study: A Promising Update in CAR T Cell Therapy
PremiumCompany Announcements
Allogene Therapeutics’ ALPHA Study: A Promising Update in CAR T Cell Therapy
3M ago
ALLO
Positive Outlook for Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Advancements and Strong Financial Position
PremiumRatingsPositive Outlook for Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Advancements and Strong Financial Position
5M ago
ALLO
Allogene Therapeutics’ Earnings Call: Cautious Optimism
Premium
Company Announcements
Allogene Therapeutics’ Earnings Call: Cautious Optimism
5M ago
ALLO
Allogene Therapeutics Advances in CAR T Therapy Development
Premium
Company Announcements
Allogene Therapeutics Advances in CAR T Therapy Development
5M ago
ALLO
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c)
PremiumThe Fly
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c)
5M ago
ALLO
Allogene Therapeutics downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Allogene Therapeutics downgraded to Underweight from Neutral at JPMorgan
6M ago
ALLO
Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
PremiumCompany Announcements
Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
7M ago
ALLO
Allogene Therapeutics Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Allogene Therapeutics Earnings Call: Progress Amid Challenges
7M ago
ALLO
Allogene Therapeutics management to meet with Piper Sandler
PremiumThe FlyAllogene Therapeutics management to meet with Piper Sandler
7M ago
ALLO
Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
Premium
Company Announcements
Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
8M ago
ALLO
Promising Pipeline and Strategic Advancements Drive Buy Rating for Allogene Therapeutics
Premium
Ratings
Promising Pipeline and Strategic Advancements Drive Buy Rating for Allogene Therapeutics
8M ago
ALLO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >